Predictors of Antiretroviral Medication Adherence Among a Diverse Cohort of Adolescents With HIV

Chandwani, Sulachni; Koenig, Linda J.; Sill, Anne; Abramowitz, Susan; Conner, Latoya C.; D’Angelo, Lawrence J.

doi:10.1016/j.jadohealth.2011.12.013

Cited by 83 publications

(88 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At baseline, a quarter of the youth presented symptoms of depression, and few presented symptoms of severe depression. The prevalence of depression reported here is similar to that observed in a subgroup of adolescent PIY (24%) [28]. Reisner et al [5] stated in their 2009 review that symptoms of depression and severe depression are strongly associated with nonadherence based on four studies conducted principally among cohorts of young African Americans.…”

Section: Discussionsupporting

confidence: 83%

Predictors and Evolution of Antiretroviral Therapy Adherence Among Perinatally HIV-Infected Adolescents in Brazil

Côté

Delmas

Succi

et al. 2016

Journal of Adolescent Health

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

Predictors and Evolution of Antiretroviral Therapy Adherence Among Perinatally HIV-Infected Adolescents in Brazil

Côté

Delmas

Succi

et al. 2016

Journal of Adolescent Health

View full text Add to dashboard Cite

“…[62][63][64] Among HIV-infected adolescents, barriers to adherence include medical, psychological, and logistical reasons. Medical barriers shown to affect adherence in youth include an AIDS diagnosis, 65 a difficult ART regimen, 65 absence of symptoms, 66 side effects of medication, 67 and dissatisfaction with the health team/system. 68 Logistical barriers such as forgetting medication doses, [65][66][67] travel, 66 and inconvenience/inconsistent routine 66,67 commonly affect adherence in youth.…”

Section: Adherence Among Adolescentsmentioning

confidence: 99%

“…Medical barriers shown to affect adherence in youth include an AIDS diagnosis, 65 a difficult ART regimen, 65 absence of symptoms, 66 side effects of medication, 67 and dissatisfaction with the health team/system. 68 Logistical barriers such as forgetting medication doses, [65][66][67] travel, 66 and inconvenience/inconsistent routine 66,67 commonly affect adherence in youth. Psychological barriers including depression/ anxiety, [69][70][71][72] perceived stigma, 69 lack of support, 72-74 behavioral and conduct problems 71 are present in more than 50% of HIV-infected youth.…”

Section: Adherence Among Adolescentsmentioning

confidence: 99%

The Adolescent and Young Adult HIV Cascade of Care in the United States: Exaggerated Health Disparities

Zanoni

Mayer²

2014

AIDS Patient Care and STDs

361

315

View full text Add to dashboard Cite

Little is known about how adolescents and young adults contribute to the declines in the cascade of care from HIV-1 diagnosis to viral suppression. We reviewed published literature from the Unites States reporting primary data for youth (13-29 years of age) at each stage of the HIV cascade of care. Approximately 41% of HIVinfected youth in the United States are aware of their diagnosis, while only 62% of those diagnosed engage medical care within 12 months of diagnosis. Of the youth who initiate antiretroviral therapy, only 54% achieve viral suppression and a further 57% are not retained in care. We estimate less than 6% of HIV-infected youth in the United States remain virally suppressed. We explore the cascade of care from HIV diagnosis through viral suppression for HIV-infected adolescents and young adults in the United States to highlight areas for improvement in the poor engagement of the infected youth population.

show abstract

“…Metabolic and pharmacokinetic changes associated with normal child development and puberty may lead to different dosing requirements depending on the growth and pubertal stage of the pediatric patient. Other complicating factors which interfere with optimizing antiretroviral therapy (ART) include unpredictable absorption of oral drugs, lack of palatable and suitable child-friendly formulations, and overall poor adherence with ART [5][6][7]. Despite these characteristics of HIV infection in infancy and childhood, the use of combination ART (cART) has greatly improved pediatric outcomes worldwide, particularly when therapy is begun early in life [8,9].…”

Section: Introductionmentioning

confidence: 99%

Use of Integrase Inhibitors in HIV-Infected Children and Adolescents

Dehority

Abadi

Wiznia

et al. 2015

Drugs

View full text Add to dashboard Cite

Resistance to antiretroviral drugs is an increasingly prevalent challenge affecting both the adult and pediatric HIV-infected populations. Though data on the safety, pharmacokinetics, and efficacy of newer antiretroviral agents in children typically lags behind adult data, newer agents are becoming available for use in HIV-infected children who are failing to respond to or are experiencing toxicities with traditional antiretroviral regimens. Integrase strand transfer inhibitors are one such new class of antiretrovirals. Raltegravir has been US Food and Drug Administration (FDA) approved for use in patients over the age of 4 weeks. Elvitegravir is a second member of this class, and has the potential for use in children but does not yet have a Pediatric FDA indication. Dolutegravir, a second-generation integrase inhibitor, is approved for those older than 12 years. This review summarizes the use of integrase inhibitors in children and adolescents, and highlights the results of recent clinical trials.

show abstract

Predictors of Antiretroviral Medication Adherence Among a Diverse Cohort of Adolescents With HIV

Cited by 83 publications

References 40 publications

Predictors and Evolution of Antiretroviral Therapy Adherence Among Perinatally HIV-Infected Adolescents in Brazil

Predictors and Evolution of Antiretroviral Therapy Adherence Among Perinatally HIV-Infected Adolescents in Brazil

The Adolescent and Young Adult HIV Cascade of Care in the United States: Exaggerated Health Disparities

Use of Integrase Inhibitors in HIV-Infected Children and Adolescents

Contact Info

Product

Resources

About